Clinical trials discussion, page-8

In her responses to St***head's "biotech investing for dummies" questions, Dr Nina deftly used every response as an opportunity to highlight DXB's progress and the many intelligent decisions taken by management to ensure the trials proceed as planned.

But the most telling comment was this snippet from Dr Nina, at about 8 minutes in, which reinforces the likelihood of positive readouts for DKD and FSGS in the coming weeks.

"....Phase 3 is the final phase before going to market. That's the stage that Dimerix is currently gearing up for, on the back of Phase 2 data expected in the middle of this year...."

If there was any remaining doubt that we should expect good news, the fact that DXB is already gearing up for Phase 3 should put that beyond question.